SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Oncology Pharmacy Practice
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Olson, K.
Right arrow Articles by Van Poznak, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olson, K.
Right arrow Articles by Van Poznak, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Significance and impact of bisphosphonate-induced acute phase responses

Karin Olson, PhD

University of Michigan Comprehensive Cancer Center

Catherine Van Poznak, MD

University of Michigan Comprehensive Cancer Center, University of Michigan, 1500 E Medical Center Drive, C346 Med Inn Building, Ann Arbor, MI 48109-0848, cvanpoz{at}umich.edu

Background: Bisphosphonates are synthetic analogs of inorganic pyrophosphates with high avidity for bone, where they bind to hydroxyapatite crystals. Bisphosphonates are effective in decreasing bone resorption, the incidence of skeletal-related events, and pain from bone metastases. These agents have recently become incorporated into the treatment regimen of patients with osteolytic and osteoblastic metastatic bone disease. Although relatively well tolerated, the initial dose(s) of intravenous aminobisphosphonates can be associated with an acute phase response, a nonspecific physiologic reaction associated with increased levels of inflammatory cytokines, fever, and flu like symptoms including fatigue, nausea, and myalgia.

Objective: The purpose of this article is to provide an updated review of the literature in this field.

Data Sources: A search of PubMed was performed using the key terms bisphosphonate, acute phase response, and cancer, and limited to publications in English. The published literature on acute phase response with bisphosphonate therapy was reviewed.

Results and Conclusions: Approximately 40% of patients receiving aminobisphosphonates experience an acute phase response, which generally occurs only on first exposure to the drug and typically last <72 h. Not all bisphosphonates induce acute phase responses to the same extent. This article reviews acute phase response in patients with metastatic bone disease treated with aminobisphosphonates. J Oncol Pharm Practice (2007) 13: 223—229.

Key Words: bisphosphonates • acute phase responses • safety • advanced cancer treatment

References

  • Coxon FP, Thompson K., Rogers MJ Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006; 6: 307—12.[CrossRef][Medline] [Order article via Infotrieve]
  • Roelofs AJ, Thompson K., Gordon S., Rogers MJ Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006; 12: 6222s—30s.[Abstract/Free Full Text]
  • Ross JR, Saunders Y., Edmonds PM, Patel S., Wonderling D., Normand C., Broadley K. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2004; 8: 1—176.[Medline] [Order article via Infotrieve]
  • Coleman RE Bisphosphonates: clinical experience. Oncologist 2004; 9: 14—27.[Abstract/Free Full Text]
  • von Moos R. Bisphosphonate treatment recommendations for oncologists. Oncologist 2005; 10: 19—24.[Abstract/Free Full Text]
  • Body JJ Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Cancer Res 2006; 12: 6258s—63s.[Abstract/Free Full Text]
  • Ceciliani F., Giordano A., Spagnolo V. The systemic reaction during inflammation: the acute-phase proteins. Protein Pept Lett 2002; 9: 211—23.[CrossRef][Medline] [Order article via Infotrieve]
  • Adami S., Bhalla AK, Dorizzi R., Montesanti F., Rosini S., Salvagno G., Lo Cascio V. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987; 41: 326—31.[Medline] [Order article via Infotrieve]
  • Conte P., Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9: 28—37.[Abstract/Free Full Text]
  • Pepys MB, Hirschfield GM C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805—12.[CrossRef][Medline] [Order article via Infotrieve]
  • Tanvetyanon T., Stiff PJ Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006; 17: 897—907.[Abstract/Free Full Text]
  • Adami S., Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf 1996; 14: 158—70.[Medline] [Order article via Infotrieve]
  • Thiebaud D., Sauty A., Burckhardt P., Leuenberger P., Sitzler L., Green JR, Kandra A., Zieschang J., Ibarra de Palacios P. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 1997; 61: 386—92.[CrossRef][Medline] [Order article via Infotrieve]
  • Schweitzer DH, Oostendorp-van de RuitM., Van der PluijmG., LowikCW, PapapoulosSE Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995; 10: 956—62.[Medline] [Order article via Infotrieve]
  • Sauty A., Pecherstorfer M., Zimmer-Roth I., Fioroni P., Juillerat L., Markert M., Ludwig H., Leuenberger P., Burckhardt P., Thiebaud D. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 1996; 18: 133—39.[Medline] [Order article via Infotrieve]
  • Pecherstorfer M., Jilch R., Sauty A., Horn E., Keck AV, Zimmer-Roth I., Thiebaud D. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res 2000; 15: 147—54.[CrossRef][Medline] [Order article via Infotrieve]
  • Hewitt RE, Lissina A., Green AE, Slay ES, Price DA, Sewell AK The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood {gamma}{delta} T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005; 139: 101—11.[CrossRef][Medline] [Order article via Infotrieve]
  • Dicuonzo G., Vincenzi B., Santini D., Avvisati G., Rocci L., Battistoni F., Gavasci M., Borzomati D., Coppola R., Tonini G. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 2003; 23: 649—54.[CrossRef][Medline] [Order article via Infotrieve]
  • Rogers MJ, Chilton KM, Coxon FP, Lawry J., Smith MO, Suri S., Russell RG Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism J Bone Miner Res 1996; 11: 1482—91.[Medline] [Order article via Infotrieve]
  • Zojer N., Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999; 21: 389—406.[CrossRef][Medline] [Order article via Infotrieve]
  • Yamaguchi K., Motegi K., Iwakura Y., Endo Y. Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. Br J Pharmacol 2000; 130: 1646—54.[CrossRef][Medline] [Order article via Infotrieve]
  • Monkkonen J., Simila J., Rogers MJ Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sci 1998; 62: PL95—102.[CrossRef][Medline] [Order article via Infotrieve]
  • Richards PJ, Amos N., Williams AS, Williams BD Pro-inflammatory effects of the aminobisphosphonate ibandronate in vitro and in vivo. Rheumatology ( Oxford) 1999; 38: 984—91.[Abstract/Free Full Text]
  • Pennanen N., Lapinjoki S., Urtti A., Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 1995; 12: 916—22.[CrossRef][Medline] [Order article via Infotrieve]
  • Kunzmann V., Bauer E., Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 1999; 340: 737—38.[Free Full Text]
  • Kunzmann V., Bauer E., Feurle J., Ton FWbi, Hans-Peter, Wilhelm M. Stimulation of gamma delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96: 384—92.[Abstract/Free Full Text]
  • Dieli F., Gebbia N., Poccia F., Caccamo N., Montesano C., Fulfaro F., Arcara C., Valerio MR, Meraviglia S., Di SanoC., SireciG., Salerno A. Induction of {gamma}{delta} T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003; 102: 2310—11.[Free Full Text]
  • Santini D., Fratto ME, Vincenzi B., La Cesa A., Dianzani C., Tonini G. Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities. BioDrugs 2004; 18: 269—78.[CrossRef][Medline] [Order article via Infotrieve]
  • Pecherstorfer M., Steinhauer EU, Rizzoli R., Wetterwald M., Bergstrom B. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: A randomized multicentric comparison to pamidronate. Support Care Cancer 2003; 11: 539—47.[CrossRef][Medline] [Order article via Infotrieve]
  • Makkonen N., Salminen A., Rogers MJ, Frith JC, Urtti A., Azhayeva E., Monkkonen J. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur J Pharm Sci 1999; 8: 109—18.[CrossRef][Medline] [Order article via Infotrieve]
  • Thompson K., Rogers MJ Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004; 19: 278—88.[CrossRef][Medline] [Order article via Infotrieve]
  • Deng X., Yu Z., Funayama H., Shoji N., Sasano T., Iwakura Y., Sugawara S., Endo Y. Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate. Toxicol Appl Pharmacol 2006; 213: 64—73.[CrossRef][Medline] [Order article via Infotrieve]
  • Monkkonen J., Pennanen N., Lapinjoki S., Urtti A. Clodronate (dichloromethylene bisphosphonate) inhibits LPS-stimulated IL-6 and TNF production by RAW 264 cells. Life Sci 1994; 54: PL229—34.[CrossRef][Medline] [Order article via Infotrieve]
  • Endo Y., Shibazaki M., Yamaguchi K., Nakamura M., Kosugi H. Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. Br J Pharmacol 1999; 126: 903—10.[CrossRef][Medline] [Order article via Infotrieve]
  • Gober HJ, Kistowska M., Angman L., Jeno P., Mori L., De Libero G. Human t cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197: 163—68.[Abstract/Free Full Text]
  • Body JJ Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 2006; 14: 408—18.[CrossRef][Medline] [Order article via Infotrieve]
  • Guarneri V., Donati S., Nicolini M., Giovannelli S., D'Amico R., Conte PF Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005; 10: 842—48.[Abstract/Free Full Text]
  • Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S., Kuhn JA, Dratch AD, D'Agati VD Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12: 1164—72.[Abstract/Free Full Text]
  • Rosen LS, Gordon D., Kaminski M., Howell A., Belch A., Mackey J., Apffelstaedt J., Hussein M., Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377—87.[Medline] [Order article via Infotrieve]
  • Rosen LS, Gordon D., Tchekmedyian S., Yanagihara R., Hirsh V., Krzakowski M., Pawlicki M., de Souza P., Zheng M., Urbanowitz G., Reitsma D., Seaman JJ Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial — the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21: 3150—57.[Abstract/Free Full Text]
  • Saad F., Gleason DM, Murray R., Tchekmedyian S., Venner P., Lacombe L., Chin JL, Vinholes JJ, Goas JA, Chen B. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458—68.[Abstract/Free Full Text]
  • Tripathy D., Body JJ, Bergstrom B. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. Clin Ther 2004; 26: 1947—59.[CrossRef][Medline] [Order article via Infotrieve]
  • Pecherstorfer M., Diel IJ Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy. Support Care Cancer 2004; 12: 877—81.[CrossRef][Medline] [Order article via Infotrieve]
  • Jackson GH Renal safety of ibandronate. Oncologist 2005; 10: 14—18.[Abstract/Free Full Text]
  • McLachlan S-A., Cameron D., Murray R., Tripathy D., Bergstrom B. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. Clin Drug Invest 2006; 26: 43—48.[CrossRef]
  • Gonzalez-Moles MA, Bagan-Sebastian JV Alendronate-related oral mucosa ulcerations. J Oral Pathol Med 2000; 29: 514—18.[CrossRef][Medline] [Order article via Infotrieve]
  • Lufkin EG, Argueta R., Whitaker MD, Cameron AL, Wong VH, Egan KS, O'Fallon WM, Riggs BL Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994; 4: 320—22.[CrossRef][Medline] [Order article via Infotrieve]
  • Migliorati CA, Casiglia J., Epstein J., Jacobsen PL, Siegel MA, Woo SB Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005; 136: 1658—68 [erratum published in J Am Dent Assoc 2006; 137: 26].[Free Full Text]
  • Coleman RE Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165—76.[CrossRef][Medline] [Order article via Infotrieve]
  • Coleman RE Skeletal complications of malignancy. Cancer 1997; 80: 1588—94.[CrossRef][Medline] [Order article via Infotrieve]
  • Smith I. Goals of treatment for patients with metastatic breast cancer. Semin Oncol 2006; 33: S2—5.[Medline] [Order article via Infotrieve]
  • Mystakidou K., Katsouda E., Stathopoulou E., Vlahos L. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates. Cancer Treat Rev 2005; 31: 303—11.[CrossRef][Medline] [Order article via Infotrieve]
  • Fulfaro F., Casuccio A., Ticozzi C., Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase iii trials. Pain 1998; 78: 157—69.[CrossRef][Medline] [Order article via Infotrieve]
  • Lipton A. Bisphosphonates and metastatic breast carcinoma. Cancer 2003; 97: 848—53.[CrossRef][Medline] [Order article via Infotrieve]
  • Mancini I., Dumon J-C., Body J-J. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 2004; 22: 3587—92.[Abstract/Free Full Text]
  • Wardley A., Davidson N., Barrett-Lee P., Hong A., Mansi J., Dodwell D., Murphy R., Mason T., Cameron D. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005; 92: 1869—76.[CrossRef][Medline] [Order article via Infotrieve]

Journal of Oncology Pharmacy Practice, Vol. 13, No. 4, 223-229 (2007)
DOI: 10.1177/1078155207080806
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Oncol Pharm PractHome page
C. A Dasanu and D. T Alexandrescu
Acute retinal pigment epithelial detachment secondary to pamidronate administration
Journal of Oncology Pharmacy Practice, June 1, 2009; 15(2): 119 - 121.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Olson, K.
Right arrow Articles by Van Poznak, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olson, K.
Right arrow Articles by Van Poznak, C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement